Evotec receives EUR 7.5 m grant for development of COVID-19 therapeutic

Evotec SE (Frankfurt Stock Exchange - EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that the Company has been selected by the German Federal Ministry of Education and Research ('BMBF') to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID 19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19.

Under the EUR 7.5 m grant, Evotec will use clinical material manufactured within its Just - Evotec Biologics manufacturing platform to initiate the clinical development of a potentially highly potent immunomodulatory molecule. Utilising the assays developed as part of the Company's global Pandemic Preparedness and Rapid Response initiative 'PRROTECT', Evotec has demonstrated potent activity of the molecule in pre-clinical in-vitro studies. The molecule has shown great potential to produce a powerful antiviral response against infections with SARS-CoV-2 ('coronavirus'). By amplifying the immune response against coronavirus infections, the molecule can potentially reduce the viral load. Thus, the early administration of this biologic may significantly lower the risk of a severe progression of COVID-19 that requires hospitalisation of patients.

Evotec intends to use the grant to initiate clinical studies assessing the safety and efficacy of the compound and to determine the optimal dose-range in healthy volunteers as well as COVID-19 patients.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: 'As we enter the third year of the COVID-19 pandemic, it has become apparent that besides continuing to build up immunity by way of vaccinations, effective therapeutics against the disease are also urgently needed. By amplifying the immune response and lowering the viral load, the molecule can help reduce the share of people requiring inpatient treatment, and thus the enormous strain the pandemic is putting on the global health systems. Having leveraged our pandemic preparedness platform 'PRROTECT', we are excited to use the grant from the BMBF to bring a potential COVID-19 therapeutic into the clinic.'

About PRROTECT

To prepare against future pandemics, Evotec has initiated the global networking initiative PRROTECT (pandemic Preparedness and Rapid RespOnse TEChnology PlaTform). PRROTECT builds on Evotec's existing anti-viral therapeutics portfolio and leverages the Company's platform to further broaden its existing modality-agnostic pipeline against viral threats, while at the same time accelerating R&D timelines for neutralising antibodies, and creating a flexible manufacturing network to deliver such therapeutics in the event of a future pandemic.

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Volker Braun

SVP, Head of Global Investor Relations & ESG

T: [phone]

E: [e-mail]

Anika Meier

Investor Relations Manager

T: [phone]

E: [e-mail]

Anja Ben Lekhal

Investor Relations Associate

T: [phone]

E: [e-mail]

Amelia Christina Gonzalez Palacios

Investor Relations & ESG Coordinator

T: + 49 40 560 81 857

E: [e-mail]

(C) 2022 Electronic News Publishing, source ENP Newswire